Canonic

Company Overview

Snapshot

Founded in March 2019, Canonic operates with 1–10 employees. The company is currently in a Pre-Funding stage. In October 2021, Canonic announced the full commercial launch of its first medical cannabis products in Israel.

Business overview

Canonic is focused on developing and bringing to market medical-grade cannabis products. The company utilizes a genomic approach, leveraging its parent company Evogene's computational predictive biology platform, to create improved cannabis varieties. Its core technology aims to enhance yield, stability, and specific metabolite composition. Canonic operates within the Agriculture & Food Technologies sector, specifically in Ag Tech, with a focus on Genetics & Input, and serves the Pharmaceuticals segment within Healthcare & Life Sciences.

Strategic signal

In October 2021, Canonic announced the full commercial launch of its first medical cannabis products in Israel. This milestone indicates the company's transition from development to market entry, validating its product pipeline and signaling its readiness to compete in the medical cannabis industry.

Company Intelligence Q&A

What is Canonic's primary focus?

Canonic aims to develop and commercialize medical-grade cannabis products by using a genomic approach to create improved cannabis varieties, focusing on yield, stability, and specific metabolite composition.

When did Canonic launch its first medical cannabis products?

In October 2021, Canonic announced the full commercial launch of its first medical cannabis products in Israel.

What was a key development for Canonic in early 2021?

In February 2021, Cannbit, a subsidiary of Tikun Olam-Cannbit, and Canonic of Evogene group announced a collaboration for the development of novel medical cannabis products.

What agreement did Canonic announce in January 2020?

In January 2020, Canonic announced an agreement with Hadassah Medical Center for pre-clinical studies to support the development of its medical cannabis products.

What was a significant regulatory approval for Canonic in late 2020?

In November 2020, Canonic received approval for the propagation of medical cannabis from the Israel Medical Cannabis Agency.